Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Sanofi Pharmaceuticals Incorporated" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Sanofi Pharmaceuticals Incorporated for you to read. Along with our medical data and news we also list Sanofi Pharmaceuticals Incorporated Clinical Trials, which are updated daily. BioPortfolio also has a large database of Sanofi Pharmaceuticals Incorporated Companies for you to search.
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) said that the European Commission granted conditional marketing authorization for Libtayo or cemiplimab to treat adu...
Sanofi will pay Lexicon Pharmaceuticals $260 million to terminate a partnership related to the development of a diabetes drug.
Regeneron Pharmaceuticals and Sanofi's Praluent has been approved by the FDA for use to reduce the overall risk of major adve -More-
Regeneron Pharmaceuticals and Sanofi's Dupixent has been approved by the FDA for use in adult patients with uncontrolled chro -More-
French drugmaker Sanofi has revealed that its CEO Olivier Brandicourt is to retire from the role, to be replaced with Paul Hudson, CEO at Novartis Pharmaceuticals. The decision was made on 6 June, when Sanofi’s Board of Directors voted unanimously to approve Brandicourt’s replacement. Hudson will take up the mantle on 1 September this year. Image caption: ...
Alnylam Pharmaceuticals has announced a collaboration with Regeneron Pharmaceuticals to discover, develop, and commercialize new RNA interference (RNAi) therapeutics for...Read More... The post Regeneron-Alnylam-Sanofi RNAi partnerships: what does the future hold? appeared first on Pharmaceutical Technology.
Lexicon Pharmaceuticals has announced a $260m settlement with Sanofi over the termination of their alliance, which focused on the development...Read More... The post Sanofi to pay Lexicon $260m over terminated Zynquista alliance appeared first on Pharmaceutical Technology.
French firm Sanofi has said it is ending its partnership with Texas-based firm Lexicon Pharmaceuticals over the development of diabetes drug Zynquista (sotagliflozin). Sanofi terminated its partnership with Lexicon over the once daily, dual SGLT1 and SGLT2 inhibitor, used in combination with insulin for both Type 1 and Type 2 diabetes. Shares in Lexicon dropped by as much as 48% on announcement of...
PARIS (dpa-AFX) - Sanofi (SNYNF, SNY) said that it terminated its partnership with Lexicon Pharmaceuticals Inc (LXRX) to develop, manufacture, and commercialize Zynquista in all ongoing global typ...
Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP recommended Dupixent be approved...
The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.
A U.S. judge on Wednesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA , which make a rival drug.
Brandicourt, who has helmed Sanofi since 2015, will retire from his CEO role this fall. Sanofi has a rule that its CEO cannot be over the age of 65.
Regeneron Pharmaceuticals and Sanofi’s Praluent (alirocumab) has received US Food and Drug Administration (FDA) approval. The drug is designed to mitigate the...Read More... The post Regeneron-Sanofi’s Praluent secures FDA approval for cardiac indications appeared first on Pharmaceutical Technology.
Regeneron Pharmaceuticals and Sanofi’s Praluent (alirocumab) has received US Food and Drug Administration (FDA) approval. The drug is designed to mitigate the...Read More... The post Regeneron-Sanofi’s Praluent secures FDA approval for cardiac illnesses appeared first on Pharmaceutical Technology.
Sanofi and Regeneron Pharmaceuticals’ Phase II trial of investigational IL-33 antibody REGN3500 (SAR440340) has met the primary endpoint of improvement...Read More... The post Sanofi and Regeneron’s REGN3500 trial meets primary endpoint appeared first on Drug Development Technology.
Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) after the type 1 and type 2 diabetes candidate showed mixed results in three Phase III trials, including disappointing outcomes among patients with chronic kidney disease (CKD). The post Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabet...
Von Maria Armental NEW YORK (Dow Jones)--Der französische Pharmakonzern Sanofi hat gemeinsam mit Regeneron Pharmaceuticals in einem langjährigen Patentstreit mit Amgen einen Sieg vor einem US-Geri...
Sanofi reported overall net sales increased by 5.5% for the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
SOUTH SAN FRANCISCO (dpa-AFX) - Sanofi has signed an agreement with Roche, under which, Sanofi will be responsible for leading FDA negotiations for the OTC switch and subsequent exclusive marketin...
Von Dave Sebastian PARIS (Dow Jones)--Sanofi beendet die Kooperation mit dem US-Pharmaunternehmen Lexicon Pharmaceuticals beim Diabetes-Medikament Zynquista, teilte der französische Pharmakonzern ...
PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced the European Commission has approved a new indication for Dupixent in chronic rhinosinusitis with nasal polyposis. Dup...
A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA , which sells a rival drug.
THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and commercialization of ZynquistaTM (sotagliflozin) and the settlement of its related disputes with Sanofi, each effective September 9, 2019. In connection with the termination, Lexicon will regain all ri